Indian Pharmaceuticals
-
{
- All
- News
- Videos
-
Health Ministry Mulls Ban On Cough Syrups For Children Under 2 Years: Report
New Delhi, April 11 (IANS) Health Ministry is reportedly considering banning prescriptions of paediatric cough syrups for children under two years and discouraging their use for those under five.
-
India's Pharma Opportunity: Expanding Global Reach In A Changing Healthcare Landscape
India's pharmaceutical industry is now at a critical juncture in its evolution.
-
Weight Loss Injection For ₹900? Three Pharma Firms Launch Affordable Semaglutide, Check Prices
Indian pharmaceutical companies have launched affordable versions of semaglutide injections following a patent expiry, significantly lowering costs for diabetes and weight management treatment and improving access for millions of patients.
-
Indian Pharma Giants Launch Low-Cost Generic Semaglutide Injections For Diabetes, Weight Management
New Delhi, March 21 (IANS) Three Indian pharmaceutical companies have launched generic versions of semaglutide injections, after the drug’s patent expired, offering lower‑cost options for patients managing Type 2 diabetes and obesity.
-
What Are Semaglutide Generics? Here's Why They Matter More In India Now
Semaglutide works by imitating the natural hormone glucagon-like peptide-1 (GLP-1), which plays a key role in managing blood sugar.
-
50+ Branded Semaglutide Generics To Enter India As Diabetes Drug Patent Expires In March 2026
Semaglutide patent in India expires in March 2026, enabling over 50 branded generic versions to enter the market, likely reducing treatment costs for diabetes and obesity patients.
-
Ozempic Revolution In India? Semaglutide Patent Expiry Sparks Generic Rush: Report
As the patent for semaglutide, the active ingredient in Ozempic, nears expiry, Indian pharmaceutical companies are preparing to launch cheaper generic versions.
-
India-US Trade Deal Likely To Offer Tariff Relief On Exported Medicines
India's pharmaceutical industry has welcomed the interim trade agreement framework between India and the US, which offers tariff relief on medicines and several other Indian exports.
-
Cancer Drug Imfinzi Gets Indian Regulator's Approval For Use In First-Line Treatment
AstraZeneca Pharma India Limited on Tuesday said it has received permission from the Central Drugs Standard Control Organisation to sell and distribute Durvalumab solution for infusion used in cancer treatment.
-
Indian Pharmaceutical Body Signs 3 Memorandums To Strengthen Drug Safety And Quality Standards
The Indian Pharmacopoeia Commission has signed memoranda with the Goa State Pharmacy Council, Quality Council of India, and HLL Infra Tech Services to strengthen drug safety, quality assurance and pharmacovigilance.
-
Health Ministry Mulls Ban On Cough Syrups For Children Under 2 Years: Report
New Delhi, April 11 (IANS) Health Ministry is reportedly considering banning prescriptions of paediatric cough syrups for children under two years and discouraging their use for those under five.
-
India's Pharma Opportunity: Expanding Global Reach In A Changing Healthcare Landscape
India's pharmaceutical industry is now at a critical juncture in its evolution.
-
Weight Loss Injection For ₹900? Three Pharma Firms Launch Affordable Semaglutide, Check Prices
Indian pharmaceutical companies have launched affordable versions of semaglutide injections following a patent expiry, significantly lowering costs for diabetes and weight management treatment and improving access for millions of patients.
-
Indian Pharma Giants Launch Low-Cost Generic Semaglutide Injections For Diabetes, Weight Management
New Delhi, March 21 (IANS) Three Indian pharmaceutical companies have launched generic versions of semaglutide injections, after the drug’s patent expired, offering lower‑cost options for patients managing Type 2 diabetes and obesity.
-
What Are Semaglutide Generics? Here's Why They Matter More In India Now
Semaglutide works by imitating the natural hormone glucagon-like peptide-1 (GLP-1), which plays a key role in managing blood sugar.
-
50+ Branded Semaglutide Generics To Enter India As Diabetes Drug Patent Expires In March 2026
Semaglutide patent in India expires in March 2026, enabling over 50 branded generic versions to enter the market, likely reducing treatment costs for diabetes and obesity patients.
-
Ozempic Revolution In India? Semaglutide Patent Expiry Sparks Generic Rush: Report
As the patent for semaglutide, the active ingredient in Ozempic, nears expiry, Indian pharmaceutical companies are preparing to launch cheaper generic versions.
-
India-US Trade Deal Likely To Offer Tariff Relief On Exported Medicines
India's pharmaceutical industry has welcomed the interim trade agreement framework between India and the US, which offers tariff relief on medicines and several other Indian exports.
-
Cancer Drug Imfinzi Gets Indian Regulator's Approval For Use In First-Line Treatment
AstraZeneca Pharma India Limited on Tuesday said it has received permission from the Central Drugs Standard Control Organisation to sell and distribute Durvalumab solution for infusion used in cancer treatment.
-
Indian Pharmaceutical Body Signs 3 Memorandums To Strengthen Drug Safety And Quality Standards
The Indian Pharmacopoeia Commission has signed memoranda with the Goa State Pharmacy Council, Quality Council of India, and HLL Infra Tech Services to strengthen drug safety, quality assurance and pharmacovigilance.
